Skip to main content
RT @drdavidliew I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something &

Dr. John Cush RheumNow

2 years 3 months ago
RT @drdavidliew I have to say: upadacitinib looks very decent for GCA. Not a panacea, but it definitely does something & good safety during trial. Would love to eventually see: - H2H comparative effect vs toci, secukinumab - structural outcomes - long-term safety #EULAR2024
Imaging is often instrumental in diagnosing and staging patients diagnosed with giant cell arteritis. A new study compared the diagnostic performance of Colour Duplex Ultrasound (CDUS), Fluor-18-deoxyglucose Positron Emission Tomography Computed Tomography and Magnetic Resonance Imaging in patients suspected of giant cell arteritis and found the CDUS had a numerically higher sensitivity (that was not statistically superior to other modalities).
EULAR has updated its treatment recommendations from the prior 2019 guidelines, since there have been several newly developed agents. The updated guidance includes 7 overarching principles and 11 recommendations regarding treatment strategy and pharmacological therapies.
RT @yuz6yusof

#EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy s

Dr. John Cush RheumNow

2 years 3 months ago
RT @yuz6yusof #EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare
Does Telemonitoring in SpA Work?
10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic dis

Dr. John Cush RheumNow

2 years 3 months ago
10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab. #EULAR2024
Select your GCA Therapy
Review of Amyloidosis

The New England Journal of Medicine has published a review of systemic amyloidosis.

https://t.

Dr. John Cush RheumNow

2 years 3 months ago
Review of Amyloidosis The New England Journal of Medicine has published a review of systemic amyloidosis. https://t.co/4507N4DwLk https://t.co/Q0MP5XXUHr
Hidradenitis suppurativa (HS) is a suppurative inflammatory skin disorder that is considered to be autoinflammatory by many. HS includes a specturm of disorders, linked by suppurative (or psoriatic) skin disease and potentially genetics. These HS-related disorders may include pyoderma gangrenosum, acne and suppurative hidradenitis, Pyogenic Arthritis, Pyoderma gangrenosum and Acne, pyogenic arthritis, PG, acne and suppurative
Medscape has published an informative review of leflunomide, drawn from Dr. Eric Ruderman’s recent lecture on the subject at the February RWCS meeting in Maui. Here are some highpoints from this Medscape article and lecture.
Future Big BiTEs (6.28.2024)

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the pas

Dr. John Cush RheumNow

2 years 3 months ago
Future Big BiTEs (6.28.2024) Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on https://t.co/V10S4oVFsv. https://t.co/AKb2qmQ2nf https://t.co/3nKuEXteXS
RT @drminidey

OP0165- incidence & risk factors of D2T RA in an early RA cohort

Factors assoc with D2T RA:
🩸

Dr. John Cush RheumNow

2 years 3 months ago
RT @drminidey OP0165- incidence & risk factors of D2T RA in an early RA cohort Factors assoc with D2T RA: 🩸 Seropositivity 🦴 Erosions 📈 Disease activity 📊 D2T pts have higher steroid doses & more commonly develop iatrogenic-related #comorbidities, e.g. osteoporosis
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US. The US FDA has also approve

Dr. John Cush RheumNow

2 years 3 months ago
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US. The US FDA has also approved 2 other biosimilars to ustekinumab, including ustekinumab-aekn (Selarsdi) and ustekinumab-auub (Wezlana). https://t.co/BgYQm39aEB https://t.co/XZhnHxPaP0
How do you manage new progressive ILD?

Dr. John Cush RheumNow

2 years 3 months ago
How do you manage new progressive ILD?
RT @drdavidliew

"We’ve got better at treating RA over the last 20 years, and it’s genuinely saving lives.
Something

Dr. John Cush RheumNow

2 years 3 months ago
RT @drdavidliew "We’ve got better at treating RA over the last 20 years, and it’s genuinely saving lives. Something to be very proud of. Let’s not forget that! 5y mortality from DANBIO (still, we still have work to do in seropos RA in men!) #EULAR2024 OP0162
×